Rgenix Reports Preliminary Phase 1a/b Clinical Data Demonstrating Immune-stimulatory Activity with RGX-104 in Advanced Cancer Patients
Preliminary Phase 1a/b data demonstrate RGX-104 modulates the innate immune system to stimulate T cell activation in a diverse group of heavily pre-treated patients with refractory solid cancers. Phase 1 dose escalation continues, and future plans include initiation of an expansion
Comments
Rgenix Announces Treatment of First Patient in Phase 1 Trial of RGX-104, its Lead Immuno-Oncology Therapeutic
Rgenix Announces Treatment of First Patient in Phase 1 Trial of RGX-104, its Lead Immuno-Oncology Therapeutic First-in-Class Cancer Therapeutic Targets the Liver X Receptor (LXR)-ApoE Pathway Identified Using Rgenix’s Discovery Platform NEW YORK CITY, N.Y., January 6, 2017 – Rgenix, Inc.,